Why It Matters
Aidoc is entering federal advocacy when FDA approval pathways for AI medical devices are modernizing, but Medicare reimbursement remains a bottleneck. Despite hundreds of FDA-cleared medical imaging AI algorithms, only two CPT category 1 payment codes exist for newer AI tools, according to Radiology Business. This gap directly threatens market viability for companies like Aidoc, whose diagnostic imaging tools detect conditions like intracranial hemorrhage and pulmonary embolism. Congress has responded with bipartisan proposals—including the Health Tech Investment Act and Ensuring Access to Critical Breakthrough Products Act—that would create faster Medicare payment pathways for FDA-approved AI devices.
By the Numbers
Aidoc Inc. reported $80,000 in fourth quarter 2025 spending with DLA Piper LLP (US)—marking the company’s first-ever lobbying disclosure. This modest investment pales compared to competitors: Medtronic spent $2.08 million on healthcare AI lobbying in early 2025, while AdvaMedDx consistently prioritizes Medicare AI coverage across multiple quarterly filings.
DLA Piper manages over $80 million in annual lobbying contracts across healthcare and technology, representing medical device companies on regulatory matters and handling AI-focused accounts like SparkCognition Inc.
The Agenda
Aidoc’s lobbying aligns with active congressional priorities around Medicare reimbursement for AI-enabled medical devices and FDA regulatory frameworks. Key relevant legislation includes the Health Tech Investment Act—which creates Medicare payment pathways for FDA-approved AI devices—and the Right to Override Act, protecting clinicians from employment retaliation for overriding AI recommendations.
A September 2025 House Energy and Commerce Committee hearing directly addressed AI in medical imaging, discussing clinical applications and reimbursement policies. Aidoc’s AI platform detects acute abnormalities—intracranial hemorrhage, pulmonary embolism, cervical spine fractures—making it directly relevant to these discussions.
Broader Context
Congressional interest in healthcare AI has intensified significantly. Multiple legislative vehicles are advancing, including proposals for automatic Medicare coverage of FDA breakthrough devices. The FDA issued January 2025 draft guidance on AI lifecycle management, restructuring approval processes while maintaining safety oversight.
Rep. Mariannette Miller-Meeks (R-IA-01), a physician, has hosted bipartisan briefings on AI’s diagnostic potential. The policy environment reflects bipartisan appetite for rapid innovation paired with safety guardrails—precisely where Aidoc’s imaging AI operates.
Competitive Landscape
Aidoc enters a crowded advocacy space. AdvaMedDx consistently prioritizes "imaging policy" and "Medicare AI coverage" in filings. Healthcare AI companies like Viz.ai and Tempus AI spent $400,000 and $240,000 respectively on 2025 lobbying. Major tech firms including Meta, Amazon, and Google have dramatically increased AI-focused federal advocacy. The shared legislative priorities suggest Aidoc’s lobbying directly competes with established industry efforts.
Between The Lines
Lawmakers have emphasized physician autonomy, clinician training, and equitable access as critical implementation issues. Bills like the HEAL-AI Act and HEALTH AI Act would fund medical AI training and research, indicating Congress views education alongside reimbursement as key policy priorities.
The Bottom Line
Aidoc’s inaugural federal lobbying effort arrives at a juncture where congressional and regulatory activity is intense, but a significant reimbursement gap remains between FDA approvals and Medicare coverage. The company’s $80,000 investment suggests it views federal engagement as necessary to navigate regulatory uncertainty and influence Medicare reimbursement pathways—the primary barrier to market adoption for AI-enabled medical imaging devices.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article